The trial of Sangamo’s gene-editing treatment for a rare and debilitating disease has got off to a good start, with no safety concerns reported so far.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
